Abraxis BioScience enters $295 milllion biopharmaceuticals deal
This article was originally published in Scrip
Executive Summary
Abraxis BioSciencehas signed a $295 million licensing agreement with ProMetic Life Sciences to develop and market four biopharmaceuticals. Abraxis said that the candidates will target markets worth potentially more than $600 million annually.